PT  - JOURNAL ARTICLE
AU  - L. Ford
AU  - D. Simon
AU  - J. Balog
AU  - N. Jiwa
AU  - J. Higginson
AU  - E. Jones
AU  - S. Mason
AU  - V. Wu
AU  - E. Manoli
AU  - S. M. Stavrakaki
AU  - J. McKenzie
AU  - D. McGill
AU  - H. Koguna
AU  - J. Kinross
AU  - Z. Takats
TI  - Rapid detection of SARS-CoV2 by Ambient Mass Spectrometry Techniques
AID  - 10.1101/2020.10.07.20207647
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.07.20207647
4099  - http://medrxiv.org/content/early/2020/10/12/2020.10.07.20207647.short
4100  - http://medrxiv.org/content/early/2020/10/12/2020.10.07.20207647.full
AB  - Ambient Ionisation Mass Spectrometry techniques: Desorption Electrospray Ionisation (DESI) and Laser Desorption – Rapid Evaporative Ionisation Mass Spectrometry (LD-REIMS) were used to detect the SARS-CoV-2 in dry nasal swabs. 45 patients were studied from samples collected between April – June 2020 in a clinical feasibility study. Diagnostic accuracy was calculated as 86.7% and 84% for DESI and LD-REIMS respectively. Results can be acquired in seconds providing robust and quick analysis of COVID-19 status which could be carried out without the need for a centralised laboratory. This technology has the potential to provide an alternative to population testing and enable the track and trace objectives set by governments and curtail the effects of a second surge in COVID-19 positive cases. In contrast to current PCR testing, using this technique there is no requirement of specific reagents which can cause devastating delays upon breakdowns of supply chains, thus providing a promising alternative testing method.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis article is independent research funded by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of HealthAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The project has been approved by Imperial College Healthcare Trust Tissue Bank (ICHTB). ICHTB HTA licence: 12275 REC approval: 17/WA/0161. Address: Imperial College Healthcare Tissue Bank Department of Surgery and Cancer, Charing Cross Hospital Fulham Palace Road London W6 8RF Tel: 020 3311 7173 Email: tissuebank{at}imperial.ac.uk All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData for this manuscript is uploaded in supplementary information